7.57
1.61%
+0.12
After Hours:
7.57
Valneva SE ADR stock is currently priced at $7.57, with a 24-hour trading volume of 21,394.
It has seen a +1.61% increased in the last 24 hours and a -1.43% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $7.58 pivot point. If it approaches the $7.11 support level, significant changes may occur.
Previous Close:
$7.45
Open:
$7.77
24h Volume:
21,394
Market Cap:
$526.69M
Revenue:
$166.43M
Net Income/Loss:
$-109.81M
P/E Ratio:
56.32
EPS:
0.1344
Net Cash Flow:
$-234.99M
1W Performance:
-2.32%
1M Performance:
-1.43%
6M Performance:
-35.79%
1Y Performance:
-21.61%
Valneva SE ADR Stock (VALN) Company Profile
Name
Valneva SE ADR
Sector
Industry
Phone
33 2 28 07 37 10
Address
6 rue Alain Bombard, Saint-Herblain
Valneva SE ADR Stock (VALN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-03-22 | Initiated | H.C. Wainwright | Buy |
Valneva SE ADR Stock (VALN) Latest News
What Analysts Are Saying About Valneva Stock
Benzinga
National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday
Benzinga
Smith & Wesson Brands Reports Upbeat Earnings, Joins America's Car-Mart, HCI Group And Other Big Stocks Moving Higher On Friday
Benzinga
McDonald's, Caterpillar And 3 Stocks To Watch Heading Into Monday
Benzinga
Expert Ratings for Valneva
Benzinga
Analyst Ratings for Valneva
Benzinga
Valneva SE ADR Stock (VALN) Financials Data
Valneva SE ADR (VALN) Revenue 2024
VALN reported a revenue (TTM) of $166.43 million for the quarter ending December 31, 2023, a -55.29% decline year-over-year.
Valneva SE ADR (VALN) Net Income 2024
VALN net income (TTM) was -$109.81 million for the quarter ending December 31, 2023, a +29.79% increase year-over-year.
Valneva SE ADR (VALN) Cash Flow 2024
VALN recorded a free cash flow (TTM) of -$234.99 million for the quarter ending December 31, 2023, a +18.88% increase year-over-year.
Valneva SE ADR (VALN) Earnings per Share 2024
VALN earnings per share (TTM) was -$1.5807 for the quarter ending December 31, 2023, a +41.84% growth year-over-year.
About Valneva SE ADR
Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium. The company also develops VLA15, a vaccine candidate that is in Phase II clinical trial against Borrelia; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; and VLA2001, a vaccine candidate that has completed Phase I/II clinical trial against SARS-CoV-2. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. The company has collaborations with Pfizer to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. Valneva SE was incorporated in 1999 and is headquartered in Saint-Herblain, France.
Cap:
|
Volume (24h):